Your session is about to expire
← Back to Search
Perceptual Learning Approaches for Cognitive Impairment
N/A
Recruiting
Led By C. Shawn Green
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to post-test 2, an average of 5-8 weeks
Awards & highlights
Study Summary
This trial studies how experience with the environment can change the way we perceive things. It will compare different learning approaches to find out which ones are the most effective in improving perceptual skills.
Who is the study for?
This trial is for individuals between 18 and 30 years old with corrected vision of at least 20/40. They should not have any history of retinal pathology or neurological disease.Check my eligibility
What is being tested?
The study tests various training tasks (like mixed difficulty, attention training, noise training) to see how they affect perceptual learning in people with cognitive impairment. It aims to understand which methods improve perception skills the most.See study design
What are the potential side effects?
Since this trial involves cognitive and perceptual exercises rather than medications, traditional physical side effects are not expected. However, participants may experience mental fatigue or frustration.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to post-test 2, an average of 5-8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to post-test 2, an average of 5-8 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Near Transfer Task
Change in Transfer to Auditory Attention
Change in Transfer to Reading
+1 moreTrial Design
13Treatment groups
Experimental Treatment
Group I: No Contact ControlExperimental Treatment13 Interventions
Participants will complete NCC training during the first phase of training. In the cross-over they will then complete either SPL, LT, SS, MD, NT, TWF, PT, SV, CF, ExAT, EnAT, MF, NCC.
Group II: C9 - Exogenous Attention Training (ExAT)Experimental Treatment3 Interventions
Participants will complete ExAT training during the first phase of training. In the cross-over they will then complete either ExAT, PT, NCC.
Group III: C8a - Complex Features (CF)Experimental Treatment3 Interventions
Participants will complete CF training during the first phase of training. In the cross-over they will then complete either CF, PT, NCC.
Group IV: C8 - Stimulus Variety (SV)Experimental Treatment3 Interventions
Participants will complete SV training during the first phase of training. In the cross-over they will then complete either SV, PT, or NCC.
Group V: C7 - Parafoveal Training (PT)Experimental Treatment7 Interventions
Participants will complete PT training during the first phase of training. In the cross-over they will then complete either PT, SV, CF, ExAT, EnAT, MF, or NCC.
Group VI: C6 - Training with Flankers (TWFExperimental Treatment3 Interventions
Participants will complete TWF training during the first phase of training. In the cross-over they will then complete eitherTWF, SPL, or NCC.
Group VII: C5 - Noise Training (NT)Experimental Treatment3 Interventions
Participants will complete NT training during the first phase of training. In the cross-over they will then complete either NT, SPL, or NCC.
Group VIII: C4 - Mixed Difficulty (MD)Experimental Treatment3 Interventions
Participants will complete MD training during the first phase of training. In the cross-over they will then complete either MD, SPL, or NCC.
Group IX: C3 - Short Staircases (SS)Experimental Treatment3 Interventions
Participants will complete SS training during the first phase of training. In the cross-over they will then complete either SS, SPL, or NCC.
Group X: C2 - Long Training (LT)Experimental Treatment3 Interventions
Participants will complete LT training during the first phase of training. In the cross-over they will then complete either LT, SPL, or NCC.
Group XI: C11 - Multisensory Facilitation (MF)Experimental Treatment3 Interventions
Participants will complete MF training during the first phase of training. In the cross-over they will then complete either MF, PT, NCC.
Group XII: C10 - Endogenous Attention Training (EnAT)Experimental Treatment3 Interventions
Participants will complete EnAT training during the first phase of training. In the cross-over they will then complete either EnAT, PT, NCC.
Group XIII: C1 - Standard Perceptual Learning (SPL)Experimental Treatment7 Interventions
Participants will complete SPL training during the first phase of training. In the cross-over they will then complete either SPL, LT, SS, MD, NT, TWF, or NCC.
Find a Location
Who is running the clinical trial?
University of Wisconsin, MadisonLead Sponsor
1,189 Previous Clinical Trials
3,168,406 Total Patients Enrolled
National Eye Institute (NEI)NIH
547 Previous Clinical Trials
1,401,017 Total Patients Enrolled
C. Shawn GreenPrincipal InvestigatorUniversity of Wisconsin, Madison
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a diagnosed eye condition affecting my retina.I am between 18 and 30 years old.I do not have any eye or neurological diseases.
Research Study Groups:
This trial has the following groups:- Group 1: C9 - Exogenous Attention Training (ExAT)
- Group 2: C8a - Complex Features (CF)
- Group 3: C8 - Stimulus Variety (SV)
- Group 4: C7 - Parafoveal Training (PT)
- Group 5: C10 - Endogenous Attention Training (EnAT)
- Group 6: No Contact Control
- Group 7: C11 - Multisensory Facilitation (MF)
- Group 8: C1 - Standard Perceptual Learning (SPL)
- Group 9: C2 - Long Training (LT)
- Group 10: C3 - Short Staircases (SS)
- Group 11: C4 - Mixed Difficulty (MD)
- Group 12: C5 - Noise Training (NT)
- Group 13: C6 - Training with Flankers (TWF
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any additional openings in this experiment for prospective participants?
"Affirmative. The clinicaltrial.gov website lists this medical trial as recruiting and states that it was initially posted on April 14th 2023. 1140 patients are needed from 2 separate sites, with the most recent edits made to the study occurring May 31st 2023."
Answered by AI
What is the current scope of enrollment for this clinical trial?
"Affirmative. The information on clinicaltrials.gov shows that this medical trial, which was unveiled on April 14th 2023, is actively recruiting volunteers. A total of 1140 individuals need to be recruited from 2 different sites for the study's completion."
Answered by AI
Is geriatric participation encouraged in this clinical endeavor?
"The current protocol for this medical examination requires that enrolled subjects are between 18 and 30 years of age. Separately, there are 5 other trials targeting minors and 33 specifically studying seniors over 65."
Answered by AI
Am I able to participate in this medical experiment?
"Those who wish to take part in this clinical trial should have some form of cognitive impairment and be aged 18-30. A total of 1140 participants are currently being recruited."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger